Review of the IDSA Practice Guidelines for the Management of Bacterial Meningitis

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(3):217-242

​ Karpov I.A., Ivanov A.S., Yurkevich I.V., Kishkurno E.P., Kachanko E.F.
bacterial meningitis practice guidelines diagnosis antimicrobial therapy
Section
Guidelines
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(3):217-242

Abstract

In this paper currently available data on the management, diagnosis and treatment of bacterial meningitis were discussed in accordance with the principles evidencebased medicine. The guideline represents data published through May 2004 in this field. The argumentation pro and contra using of diagnostic methods, timing of antimicrobial therapy and appropriateness of adjunctive therapy with corticosteroids were provided based on results of clinical trials and their quality. Modern antimicrobials and treatment regimens for bacterial meningitis in different age groups depending on presumptive or confirmed etiology were also discussed.

  • 1. Schuchat A., Robinson K., Wenger J.D., et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337:970–6.
  • 2. World Health Organization. Weekly Epidemiol Rec. Oct 17, 1997; 42:313–8.
  • 3. Gold R. Clinical aspects of meningococcal disease. In: Vedros NA, ed. Evolution of Meningococcal Disease. Boca Raton, Fla: CRC Press; 1987: 69–97.
  • 4. Beek D., Gans J. Corticosteroids in acute bacterial meningitis Cochrane Rev Abstract 2004. © 2004 The Cochrane Collaboration.
  • 5. Meningococcal Disease: Challenges in Prevention and Management John A. D. Leake, MD, MPH, Children’s Hospital, San Diego; Bradley A. Perkins, MD, Centers for Disease Control and Prevention, Atlanta Infect Med 17(5):364377, 2000. Cliggott Publishing, Division of SCP Communications.
  • 6. Kirsch E.A., Barton R.P., Kitchen L., Giroir B.P. Pathophysiology, treatment, and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996; 15:967–78.
  • 7. Feigin R.D., McCracken G.H., Jr., Klein J.O. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11:785–814.
  • 8. Rahav G., Toledano Y., Engelhard D., et al. Invasive pneumococcal infections: a comparison between adults and children. Medicine 1997; 76:295–303.
  • 9. RuizGonzales A., Falguera M., Nogues A., et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with communityacquired pneumonia. Am J Med 1999; 106:385–90.
  • 10. Jacobs M.R. Increasing importance of antibioticresistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996; 15:119–27.
  • 11. La Scolea L.J. Jr., Dryja D. Quantitation of bacteria in cerebrospinal fluid and blood of children with meningitis and its diagnostic significance. J Clin Microbiol 1984; 19:187–90.
  • 12. Hoffman J., Cetron M.S., Farley M.M., et al. The prevalence of drugresistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333:481–6.
  • 13. Pallares R., Linares J., Vadillo M., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474–80.
  • 14. Friedland I.R., McCracken G.J., Jr. Management of infections caused by antibiotic resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377–82.
  • 15. Tunkel A.R., Scheld W.M. Acute meningitis. In: Mandell G.L., Bennett J.E., Dolin R., eds. Mandell, Douglas, and Bennett‘s Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. P. 959–997.
  • 16. Hasbun R. The acute aseptic meningitis syndrome. Curr Infect Dis Rep 2000; 2:34551.
  • 17. Singh N., Paterson D.L., Chang F.Y., et al. Methicillinresistant Staphylococcus aureus: the other emerging resistant grampositive coccus among liver transplant recipients. Clin Infect Dis. 2000; 30:322–7.
  • 18. Aronin S.I. Bacterial meningitis: principles and practical aspects of therapy. Curr Infect Dis Rep 2000; 2:337–44.
  • 19. Marston B.J., Plouffe J.F., File T.M., et al. Incidence of communityacquired pneumonia requiring hospitalization: results of a populationbased active surveillance study in Ohio. JAMA 1997; 157:1709–18.
  • 20. Quagliarello V.J., Scheld W.M. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708–16.
  • 21. Steinhoff M.C. Haemophilus influenzae type b infections are preventable. Lancet 1997; 349:1186–7.
  • 22. Yang Y., Leng Z., Shen X., Lu D., Jiang Z., Rao J., et al. Acute bacterial meningitis in children in Hefei, China 19901992. Chinese Medical Journal 1996; 109:385–8.
  • 23. Levine M.M., Levine O.S. Disease burden, public perception and other factors that influence new vaccine development, implementation and continued use. Lancet 1997; 350:1386–92.
  • 24. Levine O.S., Schwartz B., Pierce N.F., Kane M. Development, evaluation and implementation of Hib vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J 1998; 17: S95–113.
  • 25. Salisbury D.M. Summary statement: The First International Conference on Haemophilus influenzae type b infection in Asia. Pediatr Infect Dis J 1998; 17:S93–5.
  • 26. Tunkel A.R. Bacterial meningitis. Philadelphia: Lippincott Williams & Wilkins, 2001.
  • 27. Marton K.I., Gean A.D. The spinal tap: a new look at an old test. Ann Intern Med 1986; 104:840–8.
  • 28. Greenlee J.E., Carroll K.C. Cerebrospinal fluid in CNS infections. In: Scheld W.M., Whitley R.J., Durack D.T., eds. Infections of the central nervous system. 2nd ed. Philadelphia: LippincottRaven, 1997. P. 899–922.
  • 29. Korein J., Cravisto H., Leicach M. Reevaluation of lumbar puncture: a study of 129 patients with papilledema or intracranial hypertension. Neurology 1959; 9:290–7.
  • 30. Horwitz. S.J., Boxerbaum B., O’Bell J. Cerebral herniation in bacterial meningitis in childhood. Ann Neurol 1980; 7:524–8.
  • 31. Hasbun R., Abrahams J., Jekel J., Quagliarello V.J. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001; 345:1727–33.
  • 32. Bonadio W.A. The cerebrospinal fluid: physiologic aspects and alterations associated with bacterial meningitis. Pediatr Infect Dis J 1992; 11:423–32.
  • 33. La Scolea L.J. Jr., Dryja D. Quantitation of bacteria in cerebrospinal fluid and blood of children with meningitis and its diagnostic significance. J Clin Microbiol 1984; 19:187–90.
  • 34. ChapinRobertson K., Dahlberg S.E., Edberg S.C. Clinical and laboratory analyses of cytospinprepared Gram stains for recovery and diagnosis of bacteria from sterile body fluids. J Clin Microbiol 1992; 30:377–80.
  • 35. Gray L.D., Fedorko D.P. Laboratory diagnosis of bacterial meningitis. Clin Microbiol Rev 1992; 5:130–45.
  • 36. Mylonakis E., Hohmann E.L., Calderwood S.B. Central nervous system infection with Listeria monocytogenes: 33 years experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore) 1998; 77:313–36.
  • 37. Feigin R.D., McCracken G.H. Jr., Klein J.O. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11:785–814.
  • 38. Maxson S., Lewno M.J., Schutze G.E. Clinical usefulness of cerebrospinal fluid bacterial antigen studies. J Pediatr 1994; 125:235–8.
  • 39. Hayden R.T., Frenkel L.D. More laboratory testing: greater cost but not necessarily better. Pediatr Infect Dis J 2000; 19:290–2.
  • 40. Tarafdar K., Rao S., Recco R.A., Zaman M.M. Lack of sensitivity of the latex agglutination test to detect bacterial antigen in the cerebrospinal fluid of patients with culturenegative meningitis. Clin Infect Dis 2001; 33:406–8.
  • 41. McCracken G.H. Jr., Sarff L.D. Endotoxin in cerebrospinal fluid: detection in neonates with bacterial meningitis. JAMA 1976; 235:617–20.
  • 42. Ni H., Knight A.I., Cartwright K., et al. Polymerase chain reaction for diagnosis of meningococcal meningitis. Lancet 1992; 340:1432–4.
  • 43. Radstrom P., Backman A., Qian N., et al. Detection of bacterial DNA in cerebrospinal fluid by an assay for simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and streptococci using a seminested PCR strategy. J Clin Microbiol 1994; 32:2738–44.
  • 44. Saravolatz L.D., Manzor O., VanderVelde N., el al. Broadrange bacterial polymerase chain reaction for early detection of bacterial meningitis Clin Infect Dis 2003; 36:40–5.
  • 45. Spanos A., Harrell F.E. Jr., Durack D.T. Differential diagnosis of acute meningitis: an analysis of the predictive value of initial observations. JAMA 1989; 262:2700–7.
  • 46. McKinney W.P., Heudebert G.R., Harper S.A., et al. Validation of a clinical prediction rule for the differential diagnosis of acute meningitis. J Gen Intern Med 1994; 9:8–12.
  • 47. Genton B., Berger J.P. Cerebrospinal fluid lactate in 78 cases of adult meningitis. Intensive Care Med 1990; 16:196–200.
  • 48. Leib S.L., Boscacci R., Gratzl O., Zimmerli W. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Clin Infect Dis 1999; 29:69–74.
  • 49. Nathan B.R., Scheld W.M. The potential roles of Creactive protein and procalcitonin concentrations in the serum and cerebrospinal fluid in the diagnosis of bacterial meningitis. In: Remington J.S., Swartz M.N., eds. Current clinical topics in infectious diseases, Vol. 22. Oxford: Blackwell Science, 2002. P. 155–65.
  • 50. Gerdes L.U., Jorgensen P.E., Nexo E., Wang P. Creactive protein and bacterial meningitis: a metaanalysis. Scand J Clin Lab Invest 1998; 58:383–93.
  • 51. Sormunen P., Kallio M.J.T., Kilpi T., Peltola H. Creactive protein is useful in distinguishing Gram stainnegative bacterial meningitis from viral meningitis in children. J Pediatr 1999; 134:725–9.
  • 52. Gendrel D., Raymond J., Assicot M., et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997; 24:1240–2.
  • 53. Viallon A., Zeni F., Lambert C., et al. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis 1999; 28:1313–6.
  • 54. Schwarz S., Bertram M., Schwab S., et al. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med 2000; 28:1828–32.
  • 55. Romero J.R. Diagnosis and management of enteroviral infections of the central nervous system. Curr Infect Dis Rep 2002; 4:309–16.
  • 56. Ramers C., Billman G., Hartin M., el al. Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction lest on patient management. JAMA 2000; 283:2680–5.
  • 57. Short W.R., Tunkel A.R. Timing of administration of antimicrobial therapy in bacterial meningitis. Curr Infect Dis Rep 2001; 3:360–4.
  • 58. Feigin R.D., Stechenberg B.W., Chang M.J., el al. Prospective evaluation of treatment of Haemophilus influenzae meningitis. J Pediatr 1976; 88:542–8.
  • 59. Feldman W.E., Ginsburg C.M., McCracken G.H. Jr. Relation of concentrations of Haemophilus influenzae type b in cerebrospinal fluid to late sequelae of patients with meningitis. J Pediatr 1982; 100:209–12.
  • 60. Lebel M.H., McCracken G.H. Jr. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83:161–7.
  • 61. Schaad U.B., Suter S., GianellaBorradori A., et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141–7.
  • 62. Feigin R.D., Kaplan S.L. Commentary. Pediatr Infect Dis J 1992; 11:698–700.
  • 63. Radetsky M. Duration of symptoms and outcome in bacterial meningitis: an analysis of causation and the implications of a delay in diagnosis. Pediatr Infect Dis J 1992; 11:694–8.
  • 64. Bonadio W.A. Medicallegal considerations related to symptom duration and patient outcome after bacterial meningitis. Am J Emerg Med 1997; 15:420–3.
  • 65. The Research Committee of the British Society for the Study of Infection. Bacterial meningitis: causes for concern. J Infect 1995; 30:89–94.
  • 66. Begg N., Cartwright K.A.V., Cohen J., et al. Consensus statement on diagnosis, investigation, treatment, and prevention of acute bacterial meningitis in immunocompetent adults. J Infect 1999; 39:1–15.
  • 67. Aronin S.I., Peduzzi P., Quagliarello V.J. Communityacquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862–9.
  • 68. Miner J.R., Heegaard W., Mapes A. Biros M, Presentation, lime to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001; 21:387–92.
  • 69. Lu C.H., Huang C.R., Chang W.N., et al. Communityacquired bacterial meningitis in adults: the epidemiology, timing of appropriate antimicrobial therapy, and prognostic factors. Clin Neurol Neurosurg 2002; 104:352–8.
  • 70. Tunkel A.R., Scheld W.M. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev 1993; 6:118–36.
  • 71. Scheld W.M., Koedel U., Nathan B., Pfister H.W. Pathophysiology of bacterial meningitis: mechanisms of neuronal injury. J Infect Dis 2002; 186:S225–33.
  • 72. Van der Flier M., Geelen S.P.M., Kimpen J.L.L.,. et al. Reprogramming the host response in bacterial meningitis: how to best improve outcome? Clin Microbiol Rev 2003; 16:415–29.
  • 73. Daoud A.S., Baticha A., AlSheyyab M., et al. Lack of effectiveness of dexamethasone in neonatal bacterial meningitis. Eur J Pediatr 1999; 158:230–3.
  • 74. DeLemos R.A., Haggerty R.J. Corticosteroids as an adjunct to treatment in bacterial meningitis. Pediatrics 1969; 44:30–4.
  • 75. Belsey M.A., Hoffpauir C.W., Smith M.H.D. Dexamethasone in the treatment of acute bacterial meningitis: the effect of study design on the interpretation of results. Pediatrics 1969; 44:503–13.
  • 76. Lebel M.H., Freij B.J., Syrogiannopoulos G.A., et al. Dexamethasone therapy for bacterial meningitis: results of two doubleblind, placebocontrolled trials. N Engl J Med 1988; 319:964–71.
  • 77. Lebel M.H., Hoyt M.J., Waagner D.C., et al. Magnetic resonance imaging and dexamethasone therapy for bacterial meningitis. Am J Dis Child 1989; 143:301–6.
  • 78. Odio C.M., Faingezicht I., Paris M., et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991; 324:1525–31.
  • 79. Kennedy W.A., Hoyt M.J., McCracken G.H. Jr. The role of corticosteroid therapy in children with pneumococcal meningitis. Am J Dis Child 1991; 145:1374–8.
  • 80. Schaad U.B., Lips U., Gnehm H.E., et al. Dexamethasone therapy for bacterial meningitis in children. Lancet 1993; 342:457–61.
  • 81. King S.M., Law B., Langley J.M., et al. Dexamethasone therapy for bacterial meningitis: better never than late? Can J Infect Dis 1994; 5:1–7.
  • 82. Wald E.R., Kaplan S.L., Mason E.O. Jr., et al. Dexamethasone therapy for children with bacterial meningitis. Pediatrics 1995; 95:21–8.
  • 83. Kanra G.Y., Ozen H., Secmeer G., et al. The beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J 1995; 14:490–4.
  • 84. Kilpi T., Peltola H., Jauhiainen T., et al. Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. Pediatr Infect Dis J 1995; 14:270–8.
  • 85. Macaluso A., Pivetta S., Maggi R.S., et al. Dexamethasone adjunctive therapy for bacterial meningitis in children: a retrospective study in Brazil. Ann Trop Paediatr 1996; 16:193–8.
  • 86. Qazi S.A., Khan M.A., Mughal N., et al. Dexamethasone and bacterial meningitis in Pakistan. Arch Dis Child 1996; 75:482–8.
  • 87. Arditi M., Mason E.O. Jr., Bradley J.S., et al. Threeyear multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998; 102:1087–97.
  • 88. Molyneux E.M., Walsh A.L., Forsyth H., et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomized controlled trial. Lancet 2002; 360:211–8.
  • 89. McLntyre P.B., Berkey C.S., King S.M., et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a metaanalysis of randomized clinical trials since 1988. JAMA 1997; 278:925–31.
  • 90. McCracken G.H. Jr. Rich nations, poor nations, and bacterial meningitis. Lancet 2002; 360:183.
  • 91. American Academy of Pediatrics. Pneumococcal infections. In: Pickering L.K., ed. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003. P. 490–500.
  • 92. Girgis N.I., Farid Z., Mikhail I.A., et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J 1989; 8:848–51.
  • 93. Thomas R., Le Tulzo Y., Bouget J., et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Intensive Care Med 1999; 25:475–80.
  • 94. Gijwani D., Kumhar M.R., Singh V.B., et al. Dexamethasone therapy for bacterial meningitis in adults: a double blind placebo control study. Neurol India 2002; 50:63–7.
  • 95. Ahsan T., Shahid M., Mahmood T., et al. Role of dexamethasone in acute bacterial meningitis in adults. J Pak Med Assoc 2002; 52:233–9.
  • 96. De Gans, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549–56.
  • 97. Paris M.M., Hickey S.M., Uscher M.I., et al. Effect of dexamethasone on therapy of experimental penicillin and cephalosporinresistant pneumococcal meningitis. Antimicrob Agents Chemother 1994; 38:1320–4.
  • 98. Cabellos C., MartinezLacasa J., Martos A., et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother 1995; 39:2158–60.
  • 99. Ahmed A., Jafri H., Lustar I., et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin and cephalosporinresistant pneumococcal meningitis. Antimicrob Agents Chemother 1999; 43:876–81.
  • 100. Klugman K.P., Friedland I.R., Bradley J.S. Bactericidal activity against cephalosporinresistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39:1988–92.
  • 101. Tunkel A.R., Scheld W.M. Corticosteroids for everyone with meningitis? N Engl J Med 2002; 347:1613–5.
  • 102. Cherubin C.E., Eng R.H.K., Norrby R., et al. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis 1989; 11:526–48.
  • 103. Peltola J., Anttila M., Renkonen O.V., et al. Randomized comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Lancet 1989; 1:1281–7.
  • 104. Lebel M.H., Hoyt M.J., McCracken G.H. Jr. Comparative efficacy of ceftriaxone and cefuroxime for treatment of bacterial meningitis. J Pediatr 1989; 114:1049–54.
  • 105. American Academy of Pediatrics, Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics 1997; 99:289–99.
  • 106. Kaplan S.L., Mason E.O. Jr. Management of infections due to antibioticresistant Streptococcus pneumoniae. Clin Microbiol Rev 1998; 11:628–44.
  • 107. Landesman S.H., Corrado M.L., Shah P.M., et al. Past and current roles of cephalosporin antibiotics in treatment of meningitis: emphasis on use in gramnegative bacillary meningitis. Am J Med 1981; 71:693–703.
  • 108. Cherubin C.E., Corrado M.L., Nair S.R., et al. Treatment of gramnegative bacillary meningitis: role of new cephalosporin antibiotics. Rev Infect Dis 1982; 4:S453–64.
  • 109. Kaplan S.L., Patrick C.C. Cefotaxime and aminoglycoside treatment of meningitis caused by gramnegative enteric organisms. Pediatr Infect Dis J 1990; 9:810–4.
  • 110. Fong I.W., Tomkins K.B. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604–12.
  • 111. Rodriguez W.J., Khan W.N., Cocchetto D.M., et al. Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy. Pediatr Infect Dis J 1990; 9:83–7.
  • 112. SaezLlorens X., Castano E., Garcia R., et al. Prospective randomized comparison of cetepime and cetotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995; 39:937–40.
  • 113. SaezLlorens X., O’Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001; 20:356–61.
  • 114. Rousseau J.M., Soullie B., Villevielle T., Koeck I.T. Efficacy of cefepime in postoperative meningitis attributable to Enterobacter aerogenes. J Trauma 2001; 50:971.
  • 115. Ahmed A. A critical evaluation of vancomycin for treatment of bacterial meningitis. Pediatr Infect Dis J 1997; 16:895–903.
  • 116. Viladrich P.F., Gudiol F., Linares J., et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35:2467–72.
  • 117. Kaplan S.L. Management of pneumococcal infections. Pediatr Infect Dis J 2002; 21:589–91.
  • 118. Kautman B.A. Infections of cerebrospinal fluid shunts. In: Scheld W.M., Whitley R.J., Durack D.T., eds. Infections of the central nervous system. 2nd ed. Philadelphia: LippincottRaven, 1997. P. 555–77.
  • 119. Aseni F., Otero M.C., PerezT’amarit D., et al. Risk/benefit in the treatment of children with imipenemcilastatin for meningitis caused by penicillinresistant pneumococcus. J Chemother 1993; 5:133–4.
  • 120. Aseni F., PerezTamarit D., Otero M.C., et al. Imipenemcilastatin therapy in a child with meningitis caused by a multiply resistant pneumococcus. Pediatr Infect Dis J 1989; 8:895.
  • 121. Rodriguez K., Kickinson G.M., Greenman R.L. Successful treatment of gramnegative bacillary meningitis with imipenem/cilastatin. South Med J 1985; 78:731–2.
  • 122. Wong V.K., Wright H.T. Jr., Ross L.A., et al. Imipenem/ cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10:122–5.
  • 123. Schmutzhard R., Williams K.J., Vukmirovits G., et al. A randomized comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 1995; 36:85–97.
  • 124. Bradley J.S., Scheld W.M. The challenge of penicillinresistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis 1997; 24:S213–21.
  • 125. Odio C.M., Puig J.R., Feris J.M., et al. Prospective, randomized, investigatorblinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999; 18:581–90.
  • 126. John C.C., Aouad C., Berman B., et al. Successful meropenem treatment of multiply resistant pneumococcal meningitis. Pediatr Infect Dis J 1997; 16:1009–11.
  • 127. Buckingham S.C., Davis Y., English B.K. Pneumococcal susceptibility to meropenem in a midSouth children’s hospital. South Med J 2002; 95:1293–6.
  • 128. Chmelik V., Gutvirth J. Meropenem treatment of posttraumatic meningitis due to Pseudomonas aeruginosa. J Antimicrob Chemolher 1993; 32:922–3.
  • 129. SegalMaurer S., Mariano N., Qavi A., et al. Successful treatment of ceftazidimeresistant Klebsiella pneumoniae ventriculitis with intra1 venous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999; 28:1134–8.
  • 130. Schonwald S., Geus I., Lisic M., et al. Ciprotloxacin in the treatment of gramnegative bacillary meningitis. Am J Med 1989; 87:248S–9S.
  • 131. WongBeringer A., Beringer P., Lovett M.A. Successful treatment of multidrugresistant Pseudomonas aeruginosa meningitis with highdose ciprotloxacin. Clin Infect Dis 1997; 25:936–7.
  • 132. Krecmery V. Jr., Filka J., Uher J., et al. Ciprofloxacin in the treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 1999; 35:75–80.
  • 133. Lipman I., Allworth A., Walis S.C. Cerebrospinal penetration of high doses of intravenous ciprotloxacin in meningitis. Clin Intect Dis 2000; 31:1131–3.
  • 134. Lo W.T., Wang C.C., Lee C.M., Chu M.L. Successful treatment of multiresistant Stenotrophomonas maltophilia meningitis with ciprolloxacin in the preterm infant. Eur J Pediatr 2002; 161:680–2.
  • 135. SaezLlorens X., McCoig C., Feris J.M., et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Intect Dis J 2002; 21:14– 22.
  • 136. Cottagnoud P., Tauber M.G. Fluoroqiuinolones in the treatment of meningitis. Curr Infect Dis Rep 2003; 5:329–36.
  • 137. Cruciani M., Navarra A., Di Perri G., et al. Evaluation of intraventicular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis 1992; 15:285–9.
  • 138. Wen D.Y., Bottini A.G., Hall W.A., Haines S.J. The intraventricular use of antibiotics. Neurosurg Clin North Am 1992; 3:343–54.
  • 139. Bayston R., Hart C.A., Barnicot M. Intraventricular vancomycin in the treatment associated with cerebrospinal fluid shunting and drainage. J Neurol Neurosurg Psychiatry 1987; 50:1419–23.
  • 140. Tunkel A.R., Kaufman B.A. Cerebrospinal fluid shunt infections. In: Mandell G.L., Bennett J.E., Dolin R., eds. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Science, 2004. P. 1126–32.
  • 141. Radetsky M. Duration of treatment in bacterial meningitis: a historical inquiry. Pediatr Infect Dis J 1990; 9:2–9.
  • 142. O’Neill P. How long to treat bacterial meningitis. Lancet 1993; 341:530.
  • 143. Water J.A., Rathore M.H. Outpatient management of pediatric bacterial meningitis. Pediatr Infect Dis J 1995; 14:89–92.
  • 144. Tice A.D., Strait K., Ramey R., et al. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29:1394–9.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared